Heart Failure and Central Sleep Apnea/ Cheyne-Stokes Respiration

1 Sin et al. American Journal of Respiratory Critical Care Medicine; 1999 2 Lafranchi et al. Circulation; 1999 3 Philippe et al. Heart; 2005 4 Javaheri et al. Circulation; 1998 5 Sin et al. American Journal of Respiratory Critical Care Medicine; 1999 Sleep-disordered breathing (SDB) is recognized as a serious health problem that impacts the cardiovascular system. Clinical studies have shown there is a high prevalence of SDB in heart failure patients. Furthermore, recent data suggests that these comorbid patients suffer equally from two distinct types of SDB, obstructive sleep apnea (OSA) and central sleep apnea (CSA). Heart failure patients with CSA typically exhibit a form of periodic breathing, known as CheyneStokes respiration (CSR), and these patients have been shown to have a very poor prognosis. Currently available positive airway pressure (PAP) therapies have had mixed results for patients with CSA/CSR. To this end, ResMed has developed the VPAP Adapt SV, the first FDA cleared PAP device to treat CSA/CSR in a home environment.This novel therapy utilizes adaptive servo-ventilation (ASV) and has demonstrated the ability to improve clinical outcomes and quality of life in heart failure patients. Prevalence of SDB in Congestive Heart Failure Patients